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ABSTRACT
A MOLECULAR BASIS FOR ERYTHROMYCIN
SENSITIVITY AND RESISTANCE
IN ESCHERICHIA £QLX
by
Harold Chittum
The effect of erythromycin on the 50S riboscanal subunit
during cell growth has been extensively investigated.
Sucrose density gradient analysis of ribosomes formed in the
presence and absence of the drug revealed a 50S specific
assembly defect is partially responsible for erythromycin's
inhibitory effects on wild type cells. Examination of two
erythromycin-resistant mutants of E. coli {N281 and N282)
revealed that mutant N281 (L22 mutant) but not N282 {L4
mutant) was assembly defective in the presence of the drug,
although only at much higher drug concentrations (300 ug/ml
vs. 75 ug/ml for wild type cells).
The altered genes from each mutant have been isolated
and sequenced. The L22 mutant was found to contain a 9 bp
deletion which eliminated codons 82-84, and the sequence MetLys-Arg from the protein. The L4 mutant had an A to G
transition mutation in codon 63 resulting in a Lys to Glu
change in the protein. Complementation of each mutant by
their respective wild type genes resulted in an increased
sensitivity to the drug in the partial diploid strains.
Two other macrolide antibiotics (oleandomycin and
spiranycin) were also examined but revealed no apparent
assembly effect on wild type cells. The MLS antibiotics also
appeared to be unable to effect assembly. However, the
erythromycin derivative azithronycin showed a similar effect
on assembly to that of the parent compound although
clarithromycin (another erythromycin derivative) did not.
These resultB suggest erythromycin and azithronycin effect
assembly through rlbosomal protein L4 and to a lesser extent
through protein L22.
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Chapter 1
Introduction

The study of antimicrobial agents has long been of
interest to researchers due to the medically relevant
knowledge which can result from their examination.

Equally

as important is the role these drugs play as molecular tools
for probing the structural and functional domains of their
cellular targets.

Examples include the use of rifaitpicin in

the study of RNA polymerase {Junjin et al., 1988), the
isoflavones, flavones and coumarins in the examination of
topoisomerase II (DNA gyrase) (Robinson et al., 1993) and
vancomycin as a means of studying the cell wall synthesis
machinery (Nagarajan, 1991).

It seems that virtually every

major conponent of the bacterial cell is a target for one
antibiotic or another, making the use of antibiotics a
powerful means of probing many cellular processes.

The

ribosome 1b no exception as it is the target of many
antibiotics: the macrolides, lincosamides, streptogrammins,
puromycin and chloramphenicol to name a few (Vasguez, 1979).
For this reason antibiotics which target the ribosome can be
extremely useful in unraveling the details of ribosome
structure and function relationships.

A case in point is the

construction of a model for the binding sites of puronycin
and chloramphenicol which helped to define the location of
the peptidyltransferase center of the large subunit (Moazed
and Noller, 1987).

The macrolides may be equally useful in

this regard pending a more through understanding of their
1
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mode(s) of action.
Recently, the macrolide antibiotics have gained new
attention due to their therapeutic importance in combating
increasingly prevalent pathogens such as Legionella spp.,
Campylobacter leiuni. and Chlamydia trachomatis (Kirst and
sides, 1989}.

The macrolides are an old and well established

group of drugs which still play a critical role in fighting
infectious diseases.

The fact that they account for 10-15%

of the worldwide oral antibiotic market makes this point
clear (Kirst, 1991).

In 1950 Brockmann and Henkel isolated

the first macrolide, pikromycin.

The name was chosen due to

the bitter taste associated with the drug.

The chemical

structures of pikromycin and other related antibiotics were
later shown to possess a common feature, a macrolactone ring.
Hence, the term "macrolide" was coined to describe this new
class of antibiotics.

The macrolides are usually grouped

according to the size of the aglycone compound as 12, 14, or
16-membered ring macrolides.

Most macrolides also contain

amino or neutral sugar moieties.

So far, five amino sugars

and 11 neutral sugars have been associated with the the
structures of these drugs.

To date only three drugs have

been found which belong to the 12-menibered ring group of
macrolides.

However, 23 compounds have been isolated which

belong to the 14-membered ring group and as of 1982, 71
compounds had been identified in the 16-membered ring
macrolide group.

Erythromycin shows the greatest

antibacterial activity on cultured bacteria of the macrolide
antibiotics which are utilized clinically (Gmnra, 1984}.

in

3
fact, the erythromycins are probably the most well
investigated members of the 14-membered ring group (Hardy et
al., 1968).
As it occurs naturally, erythronycin is produced as a
mixture of three isomers: erythromycins A, B, and C (Omura,
1984) (Figure 1). The process employs a series of fatty acid
synthase-like enzyme modules to synthesize the antibiotic
(Donadio et al., 1991). The predominant component of the
resulting mixture, erythromycin A (Omura, 1984), has been
used clinically and possesses broad spectrum activity against
both Gram positive and some Gram negative bacterial cells
(Gale et al., 1981; Nakayama, 1984).

However, one

disadvantage of the use of erythromycin is it's low stability
in an acid environment such as that of the stomach.

Under

conditions of low pH the drug degrades to an inactive
hemiketal derivative.

Therefore, chemical modification of

erythromycin A began with the goal of resolving this problem
as well as Improving the water solubility and taste of the
drug (Omura, 1984).

The result was a considerable wealth of

information concerning the structure-activity relationships
associated with the drug.
Conformational studies using NMR, CD, and X-ray
crystallography data, demonstrated that the orientation of
the hydrophilic groups (the ketone carbonyl, lactone
carbonyl, and hydroxyl groups at positions C-6 and C-ll) and
the hydrophobic groups (the methyl groups at the C-4, c-8,
and C-12 positions and the ethyl group at the c-13 position)
on the macrolactone ring and the desosamine sugar moiety play

Figure 1.

Chemical Structure of Erythromycin.

The three

molecular forms of erythromycin which occur naturally are
indicated below.

AGLTCOHZ

HEU1SAL SUGAB

Erythromycin A
Erythromycin B
Erythromycin C

OH
H
OH

CH3
CH3
H
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a key role in the biological activity of the drug (Omura,
1984).

Mao and Putterman have proposed that the 2' -hydroxyl

and 3' -dimethylamino groups (on desosamine) form hydrogen
bonds with the 23S rRNA in the ribosome.

The 11,12-hydroxyl,

9-carbonyl, and 3"-methoxyl, and most likely the 6-hydroxyl
groups of erythromycin A also form additional hydrogen bonds
(Mao and Putterman, 1969).
Although there have been extensive investigations of the
mechanism by which erythromycin and other macrolides inhibit
protein synthesis over the last quarter of a century,
progress in elucidating the exact process has been slow and
indecisive.

The inhibitory effects of erythromycin and other

related compounds have probably been most thoroughly
investigated in Escherichia coli (Corcoran, 1984; Vazquez,
1979).

In this organism, erythromycin interacts with

components of the 50S subunit associated with the
peptidyltransferase activity (Vogel et al., 1971).
Association of subunits in the presence of the antibiotic
appears to proceed normally, producing ribosomes which are
capable of peptide bond formation (catalyzed by
peptidyltransferase). Polyribosomes and elongating ribosomes
also seem to function normally in the presence of the drug
(Andersson and Kurland, 1987; Tai and Davis, 1979), although
their distribution on mRNA is apparently influenced by the
drug as observed by their altered mobilities in agarosepolyacrylamide conposite gels (Dahlberg et al., 1973).

These

observations have led to the suggestion that erythromycin
inhibits a step in translation between initiation and

elongation (Andersson and Kurland, 1987; Tai and Davis, 1979;
Vester and Garrett, 1987), or effects the P site*dependent
binding of peptidyl tRNA (Chinali et al., 1988).

In cell*

free translation systems where polypeptides are synthesized
in response to synthetic polynucleotide mRNAs, there have
been many reports of differential actions, depending on the
polynucleotide errployed in the assay.

For example, in the

translation of polyadenylic acid (coding for polylysine)
erythromycin stimulated the production of di, tri, and
tetrapeptides, but inhibited formation of oligo or
polypeptides (Omura, 1984; Tanaka and Teroka, 1966).

in a

polyuridylic acid directed system (coding for
polyphenylalanine), erythromycin failed to inhibit
polyphenylalanine formation unless the free 50S subunits were
first preincubated with the drug (Oleinick and Corcoran,
1969).

One hypothesis proposes that erythromycin may bind in

the ribosomal "tunnel" (located between the two subunits)
consequently irrtpeding the passage of nascent peptides as
translation proceeds (Contreras and Vazquez, 1977).
Unfortunately, a consensus as to the exact mechanism by which
macrolides inhibit protein synthesis has not been reached
(Cundliffe, 1980, 1990).
It has been noted that certain differences exist between
the inhibitory effects produced by various groups of
macrolides.

Therefore, some researchers have suggested that

the macrolides should be grouped into two categories
according to their effects on protein synthesis (Arevalo et
al., 1988; Seigrist et al., 1985; Tejedor and Ballesta,

1985a, 1985b, 1986).

The erythromycin group is characterized

by the presence of monosaccharides on the aglycone ring,
while the spiramycins are characterized by the presence of
disaccharides on the aglycone ring,

as

mentioned previously,

the erythromycins inhibit chain elongation, but only after
the formation of several peptide bondB has been completed.
The spiramycins, on the other hand, are thought to be more
typical peptidyltransferase inhibitors.

For example,

spiramycin is an excellent inhibitor of both the puroniycin
reaction and the so called * fragment reaction" while
erythromycin is a poor inhibitor of either unless specific
aminoacyl-tRNAs are used as a substrate (Arevalo et al.,
1989).

The identification of erythromycin-resistant mutants

which are sensitive to spiraitrycin provides sane evidence that
the binding sites of the two macrolides may not be identical
either.

Further evidence for this difference lies in the

fact that the binding site for erythromycin on the 5OS
subunit is thought to be close to, but not at, the
peptidyltransferase center (Cooperman et al., 1990).
Fluorescence energy transfer experiments have suggested a
distance of 2.3 nm (Wells and Cantor, 1980).
Studies involving ribosomes from Staphylococcus aureuB
(Mao and Putterman, 1969), Bacillus subtilis (Oleinick and
Corcoran, 1969) and E. coli (PeBtka, 1974; Teraoka, 1970)
have allowed the binding parameters of erythromycin to be
defined and have suggested features of the compound important
for binding interactions (Mao and Putterman, 1969; PeBtka,
1974).

Erythromycin was shown to bind tightly and

stoichiometrically in a X:l ratio to the 50S ribosomal
subunit from all three organisms (Oleinick and Corcoran,
1969; Mao and Putterman, 1969; Pestka, 1974).

These studies

also revealed that erythromycin is a competitive inhibitor
for the binding of virginiamycin S (deflethune and Nierhaus,
1978) and prevents the binding of chloramphenicol, lincomycin
and Bpiramycin to the 50S ribosomal subunit (Vazquez, 1979).
These compounds all inhibit peptide bond formation
reinforcing the idea that erythromycin does interact with
ribosomal components at or near the peptidyltransferase
center.

Protein L22 of the large subunit has been shown to

interact directly with virginiamycin S (DiGiambattista et
al., 1990).

Other work has shown that two different

photoreactive derivatives of erythromycin specifically bound
to protein L22 and more weakly to proteins L2, L4 and L15
(Arevalo et al., 1988).

A combination of polyacrylamide gel

electrophoresis and reverse-phase high-performance liquid
chromatography (HPLC) approaches were used to identify the
labeled proteins. In both cases hZZ labeling was inhibited by
the presence of the unlabeled drug indicating that the
labeled drugs bound the same region of the ribosome.
Other studleB have focused on the spiramycin-type
macrolides (Tejedor and Ballesta, 1985a, 1985b, 1986).
Reduction of the aldehyde group present on each drug allowed
the production of 3H-labeled dihydro derivatives of carbomycin
A, niddamycin, and tylosin.

All three of these derivatives

are capable of light-independent incorporation into ribosomal
proteins, with the first two showing photo-induced

incorporation as well.

All five labeling reactions

consistently showed protein L27 as the major labeled protein.
Site specificity was demonstrated by the ability of the
unlabeled macrolides to inhibit covalent binding.

Some have

proposed the idea that these differences can be attributed to
the different glycosidic substituents present on each drug
group (Arevalo et al., 1969).
Reconstitution experiments have been useful in
identifying key components of the erythromycin binding site.
One study identified proteins L15 and L16 as critical for
erythromycin binding to the 50S subunit and demonstrated weak
binding of the antibiotic to isolated protein L15 (Teraoka
and Nierhaus, 1976}.

Each of these proteins has been shown

to be essential for reconstitution of the peptidyltransferase
activity of the SOS subunit (Hampl et al., 1961}.

in fact,

recent studies have identified the location of these proteins
at a common site on the 50S subunit structure (Cooperman et
al., 1990; Nag et al., 1991).
Genetic studies are another important way in which
interactions between erythromycin and the ribosome have been
examined.

Resistance to erythromycin can be achieved in

several wayB.

One of the moBt extensively examined has been

resistance produced by sequence changes in the 23S ribosomal
RNA.

Although resistance to macrolides can occur as a result

of mutational changes in ribosomal components, the most
common type of resistance is defined as MLS (Macrolide,
Lincosamide and streptogramin) resistance (Goldman and Kadam,
1989).

The resistance mechanism involves the dimethylation

io

of a single adenine residue at position 2058 of the 23S rRNA
by a plasmid-encoded methyItransferase.

This mechanism has

been shown to confer drug resistance in several different
Gram positive organisms (Skinner et al., 1983).

Hie

methylation results in the production of 50S ribosomal
subunits which are unable to bind the MLS antibiotics
(Goldman and Kadam, 1989}.

Nucleotide alterations at this

same site (2058) and in adjacent residues have been shown to
lead to drug resistance as well (Douthwaite, 1992; Ettayebi
et al., 1985; Sigmund and Morgan, 1982; Vannuffel et al.,
1992; Vester and Garrett, 1987) or hypersensitivity
(Douthwaite, 1992} (Figure 2).

Sequence analysis and

protection studies have indicated that changes in either
domain II or V of the secondary structure of 23S rRNA can
give rise to erythromycin resistance (Douthwaite et al.,
1985; Moazed and Noller, 1987).

In the case of domain V, the

changes come in the form of point mutations as Figure 2
indicates.

The only domain II change found to produce

resistance to erythromycin was the deletion of nucleotides
1219 to 1230.

This has been interpreted as evidence of a

functional tertiary interaction between these two domains of
the 23S rRNA (Douthwaite et al., 1985).

The GTPase-

associated center of the 23S rRNA which is also located in
domain II has previously been implicated in antibiotic
binding.

The two drugs involved, thiostrepton and

micrococcin, both block processes associated with the
ribosomal A-site

(Egebjerg et al., 1989).

This would seem

to lend further credence to the idea of domain II's

Figure 2. Nucleotide Alterations in 23S rRNA Leading to
Erythromycin Resistance in Escherichia coli and Other
Organisms.

Abbreviations: Ans, anisomycin; Cam,

chloramphenicol; Cld, clindamycin; Ery, erythromycin; Lnc,
lincarnycin; Spr, spiramycin; r, resistant; hs,
hypersensitive; Cc, Chlamydomonas chloroplasts; E.c, £. coli;
H, Halohacterla: Hu, human mitochondria; M, mouse
mitochondria; T, Tetrahvmena cytoplasmic ribosomes; tc,
tobacco chloroplasts; Y, yeast mitochondria.
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interaction with the peptidyltransferase loop of domain V
(Douthwaite 1992}.
Another way in which resistance to erythromycin can he
produced is through alterations in a number o£ ribosomal
proteins.

Several different ribosomal protein mutants of

Escherichia ££2li resistant to high levels of erythromycin

have been isolated and characterized (Apirion, 1967; Otaka et
al., 1970; Pardo and Rosset, 1974; Pardo and Rosset, 1977;
Takata et al., 1970; Wittmann et al., 1973). Mutants altered
in proteins L4 and L22 have been the most extensively
investigated (Pardo and Rosset, 1977a; Pardo and Rosset,
1977b; Wittmann et al., 1973).

Ribosomes from one mutant

containing an altered L4 protein were shown to bind
erythromycin poorly and had a reduced peptidyltranBferase
activity,

interestingly, the distribution of polysomes in

these cells waB unaltered by growth in the presence of the
drug.

Curiously, none of these features was found for

ribosomes from another mutant which contained an altered L22
(Wittmann et al., 1973).

Mutants dependent on erythromycin

for growth have also been isolated and studied (Dabbs, 1979;
Sparling and Blackman, 1973; Wild, 1988). Protein L25 was
found to be responsible for the dependence in one of these
strains (Wild, 1988). it has also been shown that some of the
revertants from this dependence mutation in Escherichia coli
were altered in ribosomal subunit assembly and were missing
protein L19 (Wild, 1988). In fact, several erythromycin
dependent mutants have been described with either protein
S20, Lll, L15, L28, L29, or L30 missing (Dabbs, 1979) .
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Intersubunit interactions in erythromycin binding have
been implied by the observation that 1*4 erythromycinresistant mutants become sensitive to the drug if the genes
for streptomycin or spectinamycin-resistance (affecting
proteins S12 and S5) are present in the same cell as well
(Apirion and Saltzman, 1974; Saltzman and Apirion, 1976).
Drug binding to the 50S subunit has also been shown to be
dependent on the types of 3OS subunit proteins present.

This

suppression of drug-resistance suggests an interaction
between the subunits in the action of the antibiotic.
Altogether this information suggests that erythromycin
binding and inhibition involves a collection of ribosomal
components including 50S proteins L4, L15, L16, L22,
specific 23S ribosomal RNA sequences and certain
macromolecules of the 30S subunit.
Virtually all of the extensive work on erythromycin and
related 50S inhibitors has focused on their mechanism of
translational inhibition.

With the exception of the

suggestion by Vester and Garrett (1987) that erythromycin may
stimulate 50S subunit degradation, effects on the formation
or breakdown of the large subunit have not been investigated.
This point seems worth considering since the 23S rRNA, and
ribosomal proteins L4 and L22 are all involved in the
earliest parts of SOS subunit assembly, interacting at the 5'
end of the 23S rRNA (Herold and NierhauB, 1987) (Figure 3).
Two observations suggest that erythromycin may have an
additional effect on growing bacterial cells.

It has been

pointed out that the molar concentration of erythromycin
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Figure 3. Assembly Map of £. coll SOS Ribosomal Subunit.
The upper bar represents the 23S rRNA while numbered circles
designate large ribosomal subunit proteins.

Thiele arrows

indicate strong binding and thinner arrows indicate weaker
binding.
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required to affect translation in vitro is significantly
greater than the measured inhibitory concentrations in vivo
(Corcoran, 1964), suggesting a second effect of the compound
in cells.

In addition, ribosomes from an erythrontycin-

resistant mutant strain of Escherichia coli with an
alteration in ribosomal protein L22 could still bind the
antibiotic and showed normal peptidyltransferase activity.
Both of these activities were altered in another resistant
mutant with an L4 protein change (wittmann et al., 1973).
These data Buggest that a different target for erythromycin
has been effected in the L22 mutant strain compared with that
in the L4 mutant strain.
When one considers the conplexity of the mRNA
translation process, it seems apparent that molecular tools
like erythromycin can be important in unraveling the process.
The Escherichia coli ribosome with its 53 proteins and 3
ribosomal RNAs no doubt has many nuances yet to be
discovered.

The main focus of previous genetic research into

the mechanism(s) of erythromycin resistance has focused on
23S rRNA alterations.

Although certain ribosomal protein

mutants (L4 (rplD) and L22 (rpiv)) have been shown to exhibit
this phenotype, their examination has not been as extensive.
A complete understanding of the mechanism(s) is not likely to
be forth coming without consideration of these types of
mutants.

For that reason, the erythromycin resistant mutants

N281 and N282 were obtained from Dr. David Apirion (Apirion,
1967).

Hopefully this work will allow a better understanding

of a small part of this process as well as to aide in the
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design of better and more effective antibiotics for the
future.

Key to these objectives is the development of a

model for the mechanism(s) by which erythromycin produces its
inhibitory effects on bacterial growth.
the development of Buch a model.

This work describes

Chapter 2
Materials and Methods

Materials
Ampicillin, pancreatic deoxyribonuclease I (DNAse I),
erythromycin, ethidium bromide, lincomycin, lysozyme,
oleandomycin, 2,5-diphenyloxazole (PPO), ribonucleaBe
(RNAse), spiramycin, and virginiamycin Ml were purchased from
Sigma Chemical Corporation.

Acrylamide, agarose, methylene

bis-acrylamide, Triton x-100, and N,N,N’,N’tetramethylethylenediamine (TEMED) were purchased from
BioRad.

Acetic acid, mercaptoethanol, chloroform,

ethylenediaminetetracetic acid (EDTA), isoamyl alcohol,
isopropanol, trichloroacetic acid, and toluene were purchased
from Fisher Scientific.

Restriction enzymes and buffers,

phenol, sucrose, and urea were purchased from International
Biotechnologies, inc.

Hydrolink Long Ranger gel was

purchased from AT Biochemical, Inc.
R-250 stain was purchased from Kodak.

Coomassie Brilliant Blue
All culture media used

in this study were purchased from Difco Laboratories.
Radioisotopes ([5,6-3H]-uridine (40.7 Ci/mmol), [N-methyl14C]-erythronycin (54 mCi/mmol), and 35S-dATP (1355 Ci/mmol)
were purchased from New England Nuclear Products.

The Taq

polymerase kit was purchased from Promega Corporation.
Proteinase K was purchased from E.M. Biochemicals.
Y was purchased from Allied Chemical.

Pyronine

The Sequenase 2.0 kit

was purchased from United States Biochemical Corporation.
Azithrorrrycin and clarithromycin were gifts from Pfizer and
17
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Abbott Laboratories respectively.

Bacterial Strains and Plasmids

All bacterial strains and recombinant plasmids used are
described in Table 1.

Media

Bacterial strains were stored at -80°C in 1 ml aliquots
of L broth containing 20% glycerol.

Cells were grown in L

broth or tryptone broth (TB). L broth consists of 10 g
bacto-tryptone, 10 g Had, 5 g yeast extract, and 1.5 ml 1 N
NaOH dissolved in l liter of deionized water (dHao). Tryptone
broth contains 13 g tryptone and 7 g NaCl dissolved in 1
liter of dH20 {Miller, 1972}.

Plates were made with the same

media containing 1.6% agar.

Methods
Growth Experiments
Small-scale growth experiments were done in a shaking
water bath.

Ten milliliters of L broth were inoculated with

0.2 ml of an overnight culture in a 125 ml side-arm flask.
The cell density was determined using a Klett-Summerson
colorimeter with a red {Number 66) filter.

The appropriate

drug was added at a cell density of 2 x I0a cells/ml.

Large-

scale growth experiments were done on a shaking platform in a
Bally environmental room at 32°C.

cell densities for these

cultures were determined by reading the absorbance at 600 nm
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Table 1.

Bacterial Strains and Recombinant Plasmids.

Strain Mo.

Genotype

Source

SK901

F", aroE+, malA",
thi", ery6

Kushner et. al, 1977

N281

Hfr, mal+, thi+,
eryR

Apirion, 1967

M282

Hfr, mal+, thi+,
eryR

Apirion, 1967

Plasmid

Genotype

Source

pLF 1.0

l% Ecori fragment
of Xfus2 subcloned
into pBR325

Watson and Surzycki,
1983

pLF 4.6

4.6% EcoRl fragment
of Xfus2 subcloned
into pBR325

Watson and Surzycki,
1983
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in a Beckman Model 25 spectrophotometer.

Preparation of Competent Cells

This procedure was done according to the method of
Silhavy et al. (1984).

Cells were grown in L broth to an

absorbance of 0.2 at 600 nm.

The cells were then chilled on

ice for 20 minutes followed by centrifugation at 6400 x g,
for 20 minutes at 4°C in a Beckman JA-10 centrifuge.

The cell

pellet was resuspended in 200 ml of cold 100 mM CaCl2. Next!
the suspended cells were incubated on ice for 20 minutes and
repelleted as before.

Finally, the cells were resuspended in

5 ml of cold 100 mM CaCl2, made 10% in glycerol and stored at
4°C overnight.

Competent cells were used immediately for

transformation or frozen at -80°C for use later.

Bacterial Transformations

Transformation of competent cells followed the method of
Silhavy et al. (1984).

First, 0.5 ug of plasmid DMA (in a

volume of 10 ul or less) was added to a 0.2 ml aliquot of
competent cells in a 1.5 ml microfuge tube.

The suspension

was allowed to stand on ice for 1 hour, followed by a twominute heat shock at 37°C. Next, the mixture was diluted with
1 ml of L broth and incubated for 1 hour at 37°C for
phenotypic expression.

The cells were pelleted in a

microfuge and resuspended in o.l ml of L broth.

Fifty

microliters of the transformation mix was plated on an L
broth plate containing 50 ug/ml of ampicillin and placed at
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37°C overnight to select for transformed cells.

Screening Transformants

Ampicillin-resistant colonies were picked from the
overnight transformation plate and placed onto a second
ampicillin plate.

This plate was allowed to grow at 37°C

overnight and then replica plated onto a third ampicillin
plate containing 500 ug/ml erythromycin.

Complemented mutant

cells are unable to grow at this concentration of
erythromycin, while noncomplemented mutants grow slowly.

The

complemented colonies were selected and then used to make
freezer stockB.

Isolation of Plasmid DNA

Plasmid DNA. was isolated by one of two methods. The
first method employed alkaline lysis and PEG precipitation
steps.

The second method involved a boiling miniprep

procedure followed by further purification using a
commercially available "glass milk" type DNA purification
kit.

Method One. This miniprep procedure was provided by Dr.
Phillip Musich (Musich and Chu, 1993).

Cells containing the

desired plasmid were used to inoculate 20 ml of L broth
containing 50 ug/ml of ampicillin.

The cultures were then

incubated on a platform shaker at 32°C overnight.

Cells were

collected by centrifugation at 1,000 x g for 10 minutes.

The

cell pellet was resuspended in 0.6 ml of SET buffer (20%
sucrose, 50 mM Tris-HCl pH 8) by vortexing.

The suspension

was transferred to a 1.5 ml microfuge tube.

The culture tube

was then rinsed with an additional 0.7 ml of SET buffer and
transferred to the microfuge tube.

The cells were pelleted

by centrifugation for 20 seconds in a microfuge.
supernatant was poured off and discarded.

The

The remaining

pellet was resuspended in the residual liquid by vortexing
until creamy.

The suspension was mixed with 250 ul of SET

buffer by vortexing.

Cell lysis was initiated with the

addition of 0.5 ml of alkaline lysis solution (0.2 N NaOH and
1% SDS) and gentle mixing by tube inversions.

Lysis was

canqpleted by incubation at 65°C for 30 minutes with one or two
tube inversions during the incubation.

Following incubation,

375 ul of 5M KCl, pH 5.2, was added with gentle mixing.
Next, the tubes were placed on ice for at least 20 minutes,
insoluble material was pelleted by spinning the tubes in a
microfuge for 15 minutes.

The supernatant was transferred to

a clean tube and spun for an additional 10 minutes to assure
that all debris was removed.

Then the supernatant was

transferred to a clean microfuge tube and 300 ul of 27%
polyethylene glycol (PEG) in 3.3 M NaCl was added and mixed
by inversions.

The tubes were placed on ice for 2 hours and

the DNA precipitate was pelleted in a microfuge by spinning
15 minutes.

The pellet was washed with 1 ml 70% ethanol and

repelleted as before.

The pellet was then dried in a speed

vac and redissolved in 200 ul of T^E* (10 rrtM Tris-HCl pH 8.4,
1 mM EDTA). A 5 ul aliqout of DNA was removed and examined
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for purity on an agarose gel of the appropriate percentage.
To further purify the DNA., 200 ul of 5 M anmonium acetate and
400 ul of isopropanol were added with mixing by inversion.
The samples were chilled on ice for 20 minutes followed by a
15 minute spin in a microfuge.

The DNA pellet was washed

twice with 1 ml aliquots of 70% ethanol and repelleted as
before.

The pellet was vacuum dried and resuspended in the

appropriate volume of TjEq^ (l mM Tris-HCl pH 8.4, 0.1 mM
EDTA) .

Method Two. The boiling miniprep and "glass milk*
portions of this method were preformed according to the
procedures provided in an Elu-Quik DNA purification kit
purchased from Schleicher and Schuell.

CellB containing the

desired plasmid were used to inoculate 5 ml of L broth
containing 50 ug/ml of an$>icillin. A 1.5 ml portion of the
culture was transferred to a 1.5 ml microfuge tube and
pelleted in a microfuge for 1 minute.

The supernatant was

removed and the pellet was resuspended in 350 ul of STET
buffer (0.1 M NaCl, 10 irM Tris-HCl pH 8.0, 1 m EDTA pH 8.0
and 5% Triton X-100).

To this, 25 ul of freshly prepared

lysozyme (10 mg/ml in 10 mM Tris-HCl pH 8.0) was added and
mixed by vortexing.

The cells were lysed by placing the tube

in a boiling water bath for 40 seconds.

Cell debris was

pelleted by centrifugation in a microfuge for 10 minutes.
The supernatant was placed in a clean 1.5 ml microfuge tube
and the plasmid purification process was continued using the
Elu-Quik DNA purification kit and the procedure provided by
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the manufacturer.

Purified DNA was placed in an appropriate

volume of T1E0ii and examined for purity as described in the
previous section.

Isolation of Genomic DMA

Genomic DNA. was prepared according to the method of
Ausubel et al. (1969).

First, a 5 ml overnight culture grown

in L broth at 37°C was divided into three 1.5 ml microfuge
tubes.

Next, the cells were pelleted by centrifugation for 2

minutes in a microfuge and resuspended in 567 ul of T^E^

To

this, a volume of 30 ul of 10% SDS was added, followed by 3
ul of 20 mg/ml proteinase K.

The sample was then mixed by

inversion and incubated at 37°C for 1 hour.

Following

incubation, 100 ul of 5 M NaCl and 80 ul of CTAB (0.7 M NaCl,
10% hexadecyltrimethyl ammonium bromide) were added, and the
tubes were placed in a 65°C water bath for 10 minutes.

Next,

the sample was extracted with an equal volume of
chloroform:isoamyl alcohol (24:1) by inverting the tube
repeatedly.

The sample was separated into two phases by

centrifugation for 4 minutes in a microfuge.

The aqueous

layer waB transferred to a fresh microfuge tube and extracted
again with an equal volume of phenol: chloroform: isoairyl
alcohol (25:24:1).

The DNA-containing aqueous phase was

removed and precipitated by the addition of 0.6 volumes of
isopropanol.

Next, the DNA was spooled from the

precipitation interface onto a sealed Pasteur pipet and
transferred into 1 ml of 70% ethanol for washing by
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inversion.

The DNA was pelleted by centrifugation in a

microfuge for 10 minutes and rewashed a second time aB
before.

Finally, the DNA pellet was dried in a speed vac and

resuspended in 100 ul of

Concentration and purity

were determined by measuring the absorbance at 260 and 280
ran.

Polymerase Chain ReactiontPCRl

The nucleotide sequence of the S10 operon was retrieved
from Genebank (accession number X02613) (Zurawski and
zurawski, 1985).

The sequence was examined for suitable

oligonucleotide primers using the oligonucleotide analysis
program "Oligo* (National Biosciences). The program
identified two sets of forward and reverse primers
appropriate for the amplification of the rpiv and rplD genes.
The sequences of the primers were sent to Dr. Kenton L.
Lohman (Southwest Foundation for Biomedical Research; San
Antonio, Texas) for synthesis.

The sequences of the rpiv

forward and reverse primers were 5'-CGG TGG AAA GCG GAG ACA
AGA AGC C-3' and 5'-ACC AGT TTT GCG TCC AGT TCA GGC T-3',
respectively.

The sequences of the rplD forward and reverse

primers were 5'-GGC AAG AAA ATG GCA GGT CAG ATG G- 3' and 5'TTC CAT CGC AGT AGA CGC TTT TTC A- 3', respectively.

Upon

arrival the primers were cleaned by n-butanol extraction.
The concentrations of the rpiv primers were determined by Dr.
Phillip Musich (ETSU) using agarose gel analysis with known
DNA standards.

The concentrations of the rplD primers were

determined by measuring their absorbance at 260 ran.

PCR
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reactions were carried out £or the rpiv gene with the wild
type control strain and the rpiv mutant strain (N281), using
the appropriate primers.

Reactions for the rplD gene were

performed using the same control strain and the rplD mutant
strain (N282) in conjunction with their designated primers.
EnzymeBi nucleotides, and buffers were purchased as a kit
from Promega.

The following ingredients were placed into a

0,5 ml microfuge tube : 1.0 ug genomic DNA, 20 ul of 10X
buffer (0.5 M KC1, 0.1 M Tris-HCl pH 8.4, 25 nM MgCl2, 1 mg/ml
gelatin, 0.1% Tween 20, and 0.1% NP-40), 4 ul of dNTP mix
(from 10 mM solutions), 40 pmol each of the forward and
reverse primers, 4 ul of sequencing grade Taq polymerase (10
Units) and dH20 to a final volume of 200 ul.

Twenty-five

microliters of paraffin oil was then layered on top of the
sample to prevent evaporation of sample during the reaction
process.

The Bamples were placed in a Precision Scientific

GTC-l thermal cycler for thirty cycles under the conditions
of a predetermined PCR program scheme (Ehrlich et al., 1988).
The program consisted of the following steps in order of
occurrence: denaturation at 94°C for 2 minutes, annealing of
primers to target DNA at 55°C for 2 minutes, and
polymerization at 72°C for 5 minutes.

Three microliters of

the PCR reaction product from each set of reactions was
examined on a 1.14% agarose gel for spurious bands.

Finally,

the remaining portion of each reaction was run on another
1.14% agarose gel and the desired fragment electroeluted from
the gel in to purify the PCR products from contaminating
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fragments, nucleotides and primers.

Electroelution of PCR Products from Agarose Gels

PCR products were electrophoresed in a 1.14% agarose gel
containing 0.5 ug/ml ethidium bromide.

The DNA bands of

interest were located by fluorescence using a UV
transilluminator.

The bands were then excised with a razor

blade and placed into the elution wells of an electroelution
apparatus (International Biotechnologies, Inc.)

Then, 150 ill

of 7.5 M ammonium acetate/0.01% xylene cyanol solution was
placed into the V-shaped collection channels of the apparatus
and the DNA was eluted from the gel slice at 50 volts for 1
hour in tae buffer (40 nM TriB acetate, 2 nM EDTA}. The
eluted DNA in the ammonium acetate/xylene cyanol solution was
recovered by alcohol precipitation.

Agarose Gel Electrophoresis

Electrophoresis was carried out in a Hoefer submarine
minigel apparatus according to the procedure adapted by
ManiatiB et al. (1982).

The gel solution consisted of an

agarose concentration appropriate to produce fragment
resolution and 30 ml of running buffer.

The running buffer

was comprised of 89 nM Tris-borate and 2 nM EDTA, pH 8.3
(TBE). The agarose solution was heated in a boiling water
bath until melted, cooled to 55°C, and poured into a gel mold
containing an 8 well comb (well dimensions = 1 x 6 x 8 mm).
After the gel had solidified, the comb and gel tray were
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removed from the molded gel and samples were loaded.

The gel

was then electrophoresed at 50 volts until the Orange 6
tracking dye reached the desired point,

in some instances

ethidium bromide was added to the gel and running buffer
solution at a concentration of 0.5 ug/ml.

Otherwise, the

gels were stained in a solution of 0.5 ug/ml ethidium bromide
following the electrophoresis.

DNA bands were visualized by

placing the gel on a UV transilluminator.

Photographs were

taken using a Polaroid MP-4 Land camera, a red #23A UV filter
and Polaroid type 55 film.

Restrictton Enzyme Digests

Restriction digests of plasmid DNA were performed
according to the method of Maniatis et al. (1982).
Restriction enzyme buffer waB added to the DNA and diluted to
a final concentration of IX with water.

The DNA was digested

using 10 units of the appropriate restriction enzyme per
microgram of DNA.
overnight.

The digests were incubated at 37°C

Samples were then heated at 70°C for 5 minutes to

inactivate the enzyme.

The digests were then examined on an

agarose gel of the appropriate percentage.

DNA Sequencing bv Primer Extension

PCR products from the rpiv and rplD genes were sequenced
using a dideoxynucleotide chain-termination method (Sanger et
al., 1977).

This procedure was performed using materials and

instructions provided in a Sequenase 2.0 DNA sequencing kit
purchased from united states Biochemical corporation.

The
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PCR products and primers were generated as described above.
Primers for sequencing the rplD gene were the same as those
used to generate the PCR product, but were used individually.
However, a second set of primers (15-mers) were generated by
Dr. Kent Lohman for sequencing the rpiv gene.

The sequence

of this forward primer was 5' -GCG ACG CTG CTG ATA- 3'.

The

sequence of the reverse primer was 5f-CCC AGG CGA ATA CCA3'.
Templates and primers were annealed according to the
method of Ausubel et al. (1989).

The annealing reactions

consisted of 1 ug of PCR product, 1 pmol of primer (either
forward or reverse), and 2 ul of Sequenase reaction buffer
brought to a final volume of 10 ul with water.

The labeling

mix was diluted 5-fold with water and the enzyme was diluted
1:8 with the provided dilution buffer.
dATP was used per reaction set.

One microliter of 35S-

The reactions were conducted

according to the Sequenase protocol provided by the
manufacturer.

Sanples were preheated to 75°C for two minutes

and one-half of the reaction volume was loaded onto either a
6% or 8% polyacrylamide gel containing 42% urea or a 6%
Hydrolink Long Ranger gel in 89 iflM TBE (lx) poured using 0.40.8 mm wedge spacers.

The sequencing buffer was IX TBE.

The

sequencing gel was pre-run at, constant power (45 watts) for
30 minutes.

The saiqples were loaded and electrophoresed for

an appropriate time, then the second half of the reaction
volume was loaded and electrophoresed to the desired end
point.

Running and loading timeB were dependent on the

sequence position which was to be read.

Position was
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determined by following the migration of the xylene cyanol
and bromophenol blue marker dyes.

After electrophoresis was

completed, the gel was removed and placed on Whatman 3 mm
filter paper, covered with plastic wrap, and dried using a
gel drier apparatus.

Autoradiograms were prepared from the

dried gel by exposure to Kodak diagnostic X-GMAT AR film for
periods of 3 days or more, developed and read manually.

70S Ribosome Isolation

Ribosomes were isolated according to Traub et al.
(1971).

A milliliter of overnight culture was used to

inoculate 1 liter of L broth.

Cultures were grown at 32°C

until the absorbance at €00 run reached l.o.

The cells were

pelleted at 8700 x g at a temperature of 4°C for 20 minutes.
The cell pellets were washed with 10 ml R-buffer (10 nM TrisHCl pH 7.6, 10 mM magnesium acetate, 50 mM NH4C1, 0.2 mM
mercaptoethanol (ETSH)), repelleted and stored frozen at -80°C
until used.
of R-buffer.

Upon thawing, the cells were resuspended in 5 ml
Freshly prepared lysozyme was added to a

concentration of 30 ug/ml, followed by a 15 minute incubation
at room terrperature. The suspension was then frozen in an
ethanol/dry ice bath and thawed in warm water 3-4 times until
cell lysis was canplete.

Next, pancreatic DNAse I (l mg/ml

in 10 mM Tris-HCl pH 7.9, 10 mM MgS04) was added to a
concentration of 10 ug/ml.

Lysates were then allowed to

stand for 10 minutes until digestion of DNA was complete.
Cell debris was pelleted at 12,000 x g for 20 minutes at 4°C.

The supernatant was layered onto 5 ml of ribosome wash I (10%
sucrose, 2 M NH4Cl, 10 nM MgClz, 10 nM Tris-HCl pH 7.9) and
spun at 134,800 x g, for 4 hours, at 4°c in a Beckman model
L5-65 ultracentrifuge.

The ribosomal pellets were

resuspended in 1 ml R-buffer overnight at 10°C. Any insoluble
contaminants were removed by a 2 minute centrifugation in a
microfuge.

Ribosomal purity and concentration were

determined by measuring the absorbance ratio at 260 and 280
nm.

The ribosomal pellets were stored frozen at -80°C.

Ribosomal Protein isolation

Ribosomal proteins were isolated using an acetic acid
extraction method (Hardy et al., 1969).

An aliquot of

ribosomes equal to 20 a 260 units was removed from the -80°C
freezer and placed in a 1.5 ml microfuge tube for ribosomal
protein extraction.

To this, a one tenth volume of 1 M

magnesium acetate and 2 volumes of acetic acid were added to
extract the proteins and precipitate the rRNA.

This solution

was placed at 4°C and precipitation allowed to proceed for 2
hours.

Next, the rRNA was pelleted by centrifugation in a

microfuge for 2 minutes.

The supernatant was placed in a

fresh microfuge tube and ribosomal proteins were precipitated
with 5 volumes of cold acetone at -20°C for 4 hours
(Barritault et al., 1976).

Ribosomal protein was pelleted by

spinning the saiqples for 5 minutes in a microfuge.

The

supernatant was removed and the protein pellet was allowed to
dry inverted overnight.

Finally, proteins were resuspended
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in the appropriate buffer for electrophoresis.

Two-Dimensional Polyacrylamide Gels

Ribosomal proteins were separated according to the
method of Kenny et al. (1979).

This method employs an acidic

first-dimensional separation technique.

First -Dimension. Gel tubes measuring 12 cm in height
and 2 mm in diameter were used for the first-dimension tube
gel electrophoresis.

The gel tubes were filled to a 10 cm

mark with first-dimension separating gel containing 4% (w/v)
acrylamide, 0.066% (w/v) methylene bis-acrylamide, 6 M urea;
and 38 mM bis-Tris adjusted to a pH of 5.5 with acetic acid.
Gel polymerization was initiated by the addition of 1 |il of
N,N,N' ,N'-TEMED and 5 ul of 10% (w/v) amonium persulfate per
milliter of gel solution.

A flat interface was achieved by

the addition of a 100 ul of water.

After polymerization

(approximately 20 minutes) the water was removed.

Ribosomal

proteins were then dissolved in 50 ul of first-dimension
sample buffer containing 8 M urea, 40 mM mercaptoathanol, and
0.1% (w/v) pyronine Y.

The samples were loaded on top of the

polymerized gels and the gels were placed in an
electrophoresis apparatus containing 250 ml bis-Tris acetate
at pH 3.7 (upper reservoir) and pH 7.0 (lower reservoir).
The proteins were then stacked at the gel-sample interface by
electrophoresis at 0.5 milliamps per gel (constant current)
for 30 minutes.

Finally, the current was increased to 1

milliamp per gel until 45 minutes after the tracking dtye ran

I
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off the gel {3.5-4 hours).

Second-Dimension. The second dimension electrophoresis
was performed according to the method of Kaltschmidt and
Wittmann (1970).

The first-dimension tube gels were removed

using a water filled syringe and positioned on top of freshly
poured 18% slab gels.

Second-dimension gel solution (pH 4.5)

consisted of: 18% (w/v) acrylamide? 0.25% (w/v) methylene
bis-acrylamide; 48 mM KOH; 6 M urea? 0.92 M acetic acid; and
0.58% (v/v) TEMED.

Slab gels were polymerized by the

addition of 20 pi of 10% (w/v) amonium persulfate per
milliter of second-dimension gel solution.
14 cmx 12 cm x 2,5 m
solution.

The gel slab was

and held approximately 30 ml of gel

The IX running buffer (pH 4.0) contained 140 g of

glycine and 15 ml of acetic acid dissolved in 1 liter of
water.

The upper (cathode) and lower (anode) reservoirs

contained IX (400 ml) and 0.33X
respectively.

(1200 ml) running buffer

Pyronine Y was used as the tracking dye.The

electrophoresis consisted of a 30 minute stacking at 40 volts
followed by an increase to 100 volts (constant voltage) for
15 hours or until the tracking dye was approximately 2 cm
from the bottom of the gel.

Proteins were visualized by

staining for l hour with 0.1% (w/v) Cocxnassie Brilliant Blue
R-250, 50% (v/v) methanol, and 7% (v/v) acetic acid.

Gels

were destained in a solution of10% (v/v) ethanol and 5%
(v/v) acetic acid until protein
clear background.

spots were visible againsta

Photographs of stained gels were taken

UBing a Polaroid m p -4 Land camera, Polaroid type 55 film, and
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a #8 yellow filter.

Ribosomal Subunit Assembly Analysis

Assembly experiments were done according to the method
of Champney (1979).

Cells were grown in 10 ml of tryptone

broth at 37°C on a shaker water bath to a Klett density of 20
followed by addition of the desired antibiotic to test
cultures.

Next, the cells were labeled with 1 uCi 3H-uridine

and 2 ug uridine per milliliter of culture 1 hour after the
addition of the drug.

Incubation continued to a Klett

density of 100 for control cellB or until growth stopped in
cultures containing antibiotics (8-10 hours). After growth
was complete, the cells were collected by centrifugation at
2000 x g for 20 minutes.

The cell pellet was resuspended in

0.2 ml S buffer and 30 ug lysozyme was added.

S buffer

consists of 10 ium Tris-HCl, pH 7.6, 0.5 irM magnesium acetate,
50 inM NH4C1, and 6 mM mercaptoethanol. The suspension was
then frozen in an ethanol/dry ice bath and thawed in warm
water 2-3 times until cell lysis was complete.

After lysis

was complete, 10 ug of pancreatic DNAse I was added and the
cells were placed on ice for 5 minutes.

Cell debris was

removed by centrifugation at 12,000 x g for 15 minutes at 4°C.
The supematantB were then layered onto 5-20% sucrose
gradients in S buffer (no mercaptoethanol) and centrifuged at
189,000 x g for 2 hours at 4°C in a swinging bucket rotor (SW
50.1).

Typically, 30-35 fractions of three drops each were

collected and diluted with 1 ml of water.

The absorbance at

260 nm was measured for each fraction.

An equal volume of

10% TCA and 100 ug of BSA were added and the precipitated
materials were collected on Whatman type GF/A glass
microfibre filter by vacuum filtration.

Finally, the filters

were dried and counted in in a Beckman LS 3801 scintillation
counter.

The 3H counting efficiency was 82.0% in a toluene

0.25% (v/v) PPO solution.

The optical density and

radioactivity in counts per minute tcpm) from an equal number
of fractions surrounding both the 50S and 30S peaks were used
to calculate the specific activity ratios for each gradient.

Ribosomal Subunit Degradation Analysis

Cells were grown in 8 ml of tryptone broth at 37°C on a
shaker water bath to a Klett density of 60 in the presence of
0.4 uCi 3H-uridine per milliliter of culture.

The cultures

were subsequently chased with 10 ug uridine per milliter of
culture and split into two 4 ml cultures.

An additional 6 ml

of tryptone broth and erythromycin at 75 ug per milliliter of
sanple were added.

Incubation continued to a Klett density

of 100 for control cells or until growth stopped in the
erythromycin culture (8-10 hours). After growth was
canplete, the cells were collected by centrifugation at 2000
x g for 20 minutes.

Subunits were collected and counted as

previously described for ribosomal subunit asseirbly analysis.
The optical density and radioactivity in counts per minute
(cpm) from an equal number of fractions surrounding both the
50S and 30S peaks were used to calculate the specific
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activity ratios for each gradient.

Ervthromvcin Binding Reaction

Erythromycin binding reactions were performed
essentially according to the method of Teraoka (1970).
Binding reactions took place in 125 pi of reaction mixture
containing 3-4 A260 units of 70S ribosomeB, 40,000 cpm [14C] erythromycin, 50 mM Tris-HCl pH 7.8, 16 mM magnesium acetate,
and 80 nW KCl.

The samples were incubated at 37°c for 15

minutes, immediately immersed in an ice bath and diluted with
3 ml of cold wash buffer.

WaBh buffer contained 25 mM Tris-

HCl pH 7.8, 60 mM KCl, and 20 mM magnesium acetate.

The

diluted mixture was then vacuum filtered onto a 0.45 um
Millipore type HAWP filter prewetted with wash buffer.

The

filters were then washed five times with wash buffer, dried,
and counted as previously described for ribosomal subunit
assembly analysis.

The [M C] counting efficiency was 91.6%.

Chapter 3
Results

Experimental Results
Two-dimensional Electrophoresis

Previously, Wittmann et al. (1973) found that mutants
N281 and N282 contained alterations in ribosomal proteins L22
and L4 respectively.

These findings were initially based on

genetic mapping studies.

Later, two-dimensional

electrophoretic analysis of the ribosomal proteins of the
mutants revealed that strain N281 had an altered
electrophoretic mobility for protein L22.

The other mutant

did not appear to exhibit any clear mobility changes in the
gel system used.

However, the researchers were able to

confirm the previous mapping results (which implicated
protein L4) using a chromatographic separation technique.
That technique revealed that protein L4 of mutant N282 had an
altered elution profile from a carboxymethyl cellulose column
at pH 5.6 (Osawa et al., 1969).

When conpared to the pH 8.6

first-dimension separation used in the previous
polyacrylamide gel electrophoresis, it seemed likely that the
L4 protein from this mutant might have a detectably altered
mobility if the electrophoresis was at or near pH 5.6.

The

two-dimensional electrophoresis procedure of Kenny et al.
(1979) employs a first-dimension separation at pH 5.5.
Therefore, it seemed likely that the L4 protein from this
mutant (as well as the L22 mutant) might be better resolved
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in that gel system.
To investigate this possibility, ribosamal proteins from
both mutants were electrophoresed using the separation method
of Kenny et al. (1979).

As Figures 4A and B indicate, the

mutant proteins from each strain showed a significantly
decreased electrophoretic mobility in the first-dimension gel
at pH S.5. This indicates that the altered protein from each
mutant has a more negative overall charge at pH 5.5 than do
the wild type proteins from strain SK901 (Figure 5).

In

addition, the mobility of L4 was normal in the L22 mutant
strain as was the L22 protein in the L4 mutant strain (Figure
4).
Sequencing the rolv and rnlD genes

In order to deteimine the exact nature of the mutation
responsible for erythrontycin resistance in these mutants it
was necessary to sequence the altered genes.

Therefore, the

rpiv (L22) and xplD (L4) genes were anplified from the
genomic DNA isolated from the mutant and wild type strains
using the (PCR) and a series of oligonucleotide primers 25
nucleotides in length.

The L22 and L4 genes were contained

in 926 bp and 846 bp PCR products, respectively (Figures 6
and 7).

Purification of products away from spurious bands,

primers and nucleotides was accomplished by electrophoresis
on a 1.0% agarose gel (Figure 8).

The desired bands were

then sliced from the gel and the DNA electroeluted.
The purified PCR products were then sequenced to
determine the mutational changes in the genes responsible for

Figure 4.

t w o -dimensional electrophoresis of mutant

RIBOSOMAL PROTEINS.

Ribosomal proteinB from strains N282 (A)

and N281 (B) separated by the electrophoretic method of Kenny
et al. {1979). Arrows indicate the positions of both wild
type (N) and mutant (M) ribosomal proteins.
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Figure 5.

TWO-DIMENSIONAL ELECTROPHORESIS OF WILD TYPE

RIBOSOMAL PROTEINS.

ElectrophoreBis of ribosomal proteins

from £. coli strain SK901 (Control) by the method of Kenny et
al. (1979).
L22 proteins.

Arrows indicate the position of wildtype L4 and
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Figure 6.

SEQUENCE OF rplV PCR PRODUCTS.

The positions of

primers used for PCR amplification (l»22 F-l and R-l) and
sequencing of the rplV gene (D22 F-2 and R-2) are indentified
by parallel lines.

The wild type sequence indicated below is

in accordance with that reported by Zuraweki and Zurawski
(1985).

1

L22_ F-l
CGGTGGAAAG CGGAGACAAG AAGCCCCTGC GCACFK3GTC CCGTCGTTCA

51

ACGATCTTTC CTAACATGAT CGGTITGACC ATOGCTGTCC ATAATGGTCG

101

TCAGCACGTT CCGGTATTIG TAACCGACGA AATCGTTGGT CACAAACTGG

151
201

GTQAATTCGC ACCGACTCGT ACTTATCGCG GCCACGCTGC TGATAAAAAA
1*22 F-2
GCGAAGAAGA AATAAGGTAG GAGGAAGAGA TGGAAACTAT CGCTAAACAT

251

CGCCATBCTC GTTCTTCTGC TCAGAAGGTT CGCCITGTTG CTGACCTGAT

301

TCGCGGTAAG AAAGTGTCGC AGGCTCTGGA TATTTTGACC TACACCAACA

351

AGAAAGCGGC TGTACTGGTC AAGAAAGTTC TGGAATCTGC CATTGCTAAC

401

GCTGAACACA ACGATGGCGC TGACATTGAC GATCTGAAAG TTACGAAAAT

451

TTTCGTAGAC GAAGGCCCGA GCATGAAGOG CATTATGCCG CGTGCAAAAG

501

GT0GTGCAGA TCGCATCCTG AAGCGCACCA GCCACATCAC TGTGGTTGTG

551
601

TCCGATCGCT GAGACTCTGG AGACTAGCAA TGGGTCAGAA AGTACATCCT
L22.:Rz2
AATGGTATTC GCCTGGGTAT TGTAAAACCA TGGAACTCTA CCTGG7TTOC

651

GAACACCAAA GAATTCGCTG ACAACCTGGA CAGCGATTFP AAAGTACGTC

701

AGTACCTOAC TAAGGAACTG GCTAAAGCGT CCGTATCTCG TATCGTTATC

751

GAGCGTCCGG CTAAGAGCAT CCGTGTAACC ATTCACACTG CTCGCCCGGG

801

TATCGTTATC GGTAAAAAAG GTGAAGACGT AGAAAAACTG CGTAAGGTCG

851

TAGOGGACAT CGCTGGOGTT CCTGCACAGA TCAACATCGC CGAAGTTCGT
L22 R-l
AAGCCTGAAC TGGACGCAAA ACTGGT

901
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Figure 7.

SEQUENCE OF rplD PCR PRODUCTS.

The positions of

primers used for PCR amplification and sequencing of the rplD
gene {L4 F and R) are indicated by parallel lines.

The wild

type sequence indicated below is in accordance with that
reported by Zurawski and Zurawski (1985).

L4 F

1

GGCAAGAAAA TGGCAGGTCA GATGGGTAAC GAACGTGTAA COGTTCAGAG

51

CCTTGACGTA GTACGCGTTG ACGCTGAGCG CAACCTGCTG CTGGTTAAAG

101

GTGCTGTCCC GGGTGCAACC GGTAGCGACC TGATCGTTAA ACCAGCTGTG

151

AAGGCGTAAG GAGATAGCAA TGGAATTAGT ATTGAAAGAC GCGCAGAGCG

201

CGCTGACTGT TTCOGAAACT ACCTPCGGTC GTGATTTCAA CGAAGCGCTG

251

GTTCACCAAG TTGTTGTrGC TTATGCAGCT GGTGCTCGTC AGGGTACTCG

301

TGCTCAGAAG ACTCGTGCTG AAGTAACTGG ttcoggtaaa AAACCGTGGC

351

GCCAGAAAGG CACOGGCCGT GCGCGTTCTG GTTCTATCAA GAGCCCGATC

401

TGGCGTTCTG GTGGCGTGAC CTTTGCTGCT CGTCCGCAGG ACCACAGTCA

451

AAAAGTTAAC AAGAAAATGT ACCGCGGCGC GCTGAAAAGC ATCCTGTCCG

501

AACTGGTACG TCAGGATCGT CTGATCGTTG TCGAGAAGTT CTCTGTAGAA

551

GCGCCGAAAA CTAAGCTGCT GGCACAGAAA CTGAAAGACA TGGCTCTGGA

601

AGATGTGCTG ATCATCACCG GTGAGCTGGA CGAAAACCTG TTCCTGGCTG

651

CGCGCAACCT GCACAAGGTT GACGTACGCG ATGCAACTGG TATCGACCCG

701

GTTAGCCTGA TOGCCTTOGA CAAAGTCGTA ATGACTGCTG ATGCTGTTAA

751

GCAAGTTGAG GAGATGCTGG CATGATTCGT GAAGAACGTC TGCTGAAGGT

801

GCTGCGTGCA CCGCACGTPT CTGAAAAAGC GTCTACTGCG ATGGAA

i,4 n
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Figure 8.

PURIFICATION OF PCR PRODUCTS.

A three microliter

aliquot oC each PCR reaction was examined on a 1% agarose
gel.

Lanes 1-2:

PCR products obtained from the

amplification of the rplV (L22) geneB of strains N281 and
SK901 respectively.

Lanes 4-5:

PCR products amplified from

the rplD (L4) genes of strains N282 and SK901 respectively.
Lane 3:

Commercially available DNA size standards obtained

from Bio Ventures, Inc.

1 2 3 4 5

h « io o o
-«700
**500
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conferring erythromycin resistance.

The rplD sequence of

strain N282 revealed an A->G transition mutation in the first
position of codon 63 (Figure 9A). This change would result
in a Lys -> Glu change in the L4 protein and would account
for the reduced gel mobility of the mutant protein at pH 5.5.
Surprisingly, the rplV gene of strain N281 revealed a 9 bp
deletion eliminating codons 82-84 in the gene and resulting
in the loss of the tripeptide sequence Met-Lys-Arg from the
L22 protein (Figure 9B). This loss would reduce the mobility
of the protein at pH 5.5, similar to that of the L4
alteration.

Notably, a 4 bp direct repeat (GCAT) was found

in the wild type sequence flanking the L22 deletion site.
This may be indicative of some type of secondary structure
(i.e. stem-loop) participating in the deletion of the
effected sequence.
Complementation Experiments

Antibiotic sensitivity is well known to be genetically
dominant to resistance in bacterial cells which are
merodiploid for the resistance gene (Nomura and Engbaek
1972).

In order to examine this phenomenon as it relates to

these mutants, strains N281 and N282 were transformed with
plasmids pLF 1.0 and pLF 4.6, respectively.

Each of these

plasmid constructs are derived from pBR325.

Plasmid pLF 1.0

contains the L22 gene on a 0.5 kb EcoRX restriction fragment
of bacteriophage Afus2 (which contains the E. coll S10
operon). Therefore, pLF 1.0 is capable of complementing
mutations in the gene for protein 1 2 2 (Figure 10).

In
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Figure 9.

dna

AND RIBOSOMAL PROTEIN SEQUENCE changes in

MUTANTS N282 and N281.

(A) The Lys to Glu alteration, found

in the mutant L4 (N282) protein is highlighted in bold.

(B)

The Met-Lys-Arg sequence deletion in the L22 mutant, N281 is
indicated in bold and the two 4-bp repeats (GCAT) are double
underlined.

A
60

65

SK901 L4
SK901 rplD

-Trp-Arg-Gln-Lya-Gly-Thr-Gly-TGG CGC CAG AAA GGC ACC GGC-

N282 L4
N282 rplD

-Trp-Arg-Gln-Glu-Gly-Thr-Gly-TGG CGC CAG GAA GGC ACC GGC-

SK901 1*22
SK901 rplV

80
85
-Pro-Ser-Met-Lys-Arg-Ile-Met-COG AGO ATG AAG CGC ATT ATG-

N281 1.22

-Pro-Ser-ile-Met-

N281 rplV

-CCG AGC ATT ATG-

B
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Figure 10.

ORIGIN OF pLF PLASMID INSERTS.

Map of the E-

£Oli S10 ribosomal operon contained in the Xfus 2 genome.
Arrows indicate the EcoRl sites used to generate the pLF 1.0
and pLF 4.6 inserts used for complementation of the rplD and
rplV genes.

S10 Operon
tfAViV

1

VA v .v/j

P S10 S10 L3 U: L23 L2 SI9 122 S3 LI6 L29 SI 7

T

2.3Kb
pLF 4.6

TT

0.5Kb
pLF 1.0
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addition, mutations which occur in the gene for protein L4
can be complemented using plasmid pLF 4.6, which contains the
L4 gene on a 2.3 kb EcoRI fragment of the Sio operon (Figure
10).

The growth rates of the mutant cells with and without
coirplementing plasmids were measured in the presence and
absence of erythromycin.

As Table 2 indicates, both mutant

strains showed a reduced rate of growth with increasing
concentrations of erythromycin.

The mutants grew about 2.5

times more slowly in the presence of 600 ug/ml of
erythronycin.

Each complemented strain became more sensitive

to erythromycin in the presence of the wild type gene.

N281

(pLF 1.0) grew 7.5 times more slowly at this same final
concentration, while N2B2 (pLF 4.6) grew 3.7 times more
slowly.

These results are consistent the known dominance of

erythromycin sensitivity to resistance in merodiploid cells
(Nomura and Engbaek, 1972).

However, N281 (pLF 1.0) was more

affected by higher concentrations of the drug compared with
N281 than was N282 (pLF 4.6) compared with its plasmid-free
parent N282.
Since wild type cells will not grow at an erythromycin
concentration of 300 ug/ml or greater (Apirion, 1967) these
results indicate both mutant and wild type ribosomes are
being assembled in complemented mutants.

It seemed likely

therefore, that the differences in the degree of growth
inhibition between the two complemented mutants might be
reflected in differing amounts of mutant protein found under
each condition for each complemented mutant.

To test this
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Table 2. Growth Rates o£ Mutant and Plasmid-Complemented
Cells in the Presence and Absence of Erythromycin.

Erythromycin (ug/ml)
Strain

_Q_

iQjQ

M281

45

60

90

105

N281 (pLFl.O)

40

85

160

300

N282

45

55

75

115

N282 (pLF4.6)

35

65

70

130

m .

Data points in the table above indicate doubling times in
minutes.

hypothesis each complemented mutant was grown in either the
presence or absence of 300 ug/ml of erythromycin.

Ribosomes

were collected from the cells and their proteins were
examined on two-dimensional polyacrylamide gels (Figures U A 
DI. in each instance mutant protein predominated in the
presence of the antibiotic, while wild type protein was most
abundant in the absence of the drug.

However, as Table 3

indicates, the ratios between mutant and wild type protein
were not the same for each of the merodiploids. These
findings are quite consistent with the differences in growth
rate found between the two complemented mutants obtained in
the previous experiment (Table 2},
One possible explanation for these differences is that
plasmid copy number might differ depending on the type of
growth conditions used (i.e. erythromycin present or absent).
In order to examine this possibility, plasmidB were recovered
from equal numbers of each of the complemented cells and cut
with EcoRl to release the complementing inserts (Figure 12).
Image analysis of the gel negative was then used to compare
the amount of plasmid present under each growth condition
(Table 4).

These analyses revealed essentially no

differences in plasmid copy number between a given
merodiploid grown tinder either condition.

This indicates

that differences in incorporation of mutant versus wildtype
protein are real and not a phenomenon resulting from plaBmid
copy number changes found under the two conditions.
The percent of [14C] -erythromycin binding to 70S
ribosomes was used to obtain another estimate of the ratio of

Figure 11.

TWO-DIMENSIONAL ELECTROPHORESIS OF RIBOSOMAL

PROTEINS FROM COMPLEMENTED CELLS. (A-B) Enlargement of the
L22 region of a gel for ribosomal proteins isolated from N281
(pLF 1.0) cellB grown in the presence (A) and absence (B) of
erythromycin (300 ug/ml).

(C-D) Enlargement of the Li region

of a gel for ribosomal proteins isolated from N282 (pLF 4.6)
cells grown in the presence (C) and absence (D) of
erythronycln (300 ug/ml). Relative positions of the L4 and
L22 proteins are indicated.
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Table 3.

Quantitation o£ RiboBomal Proteins from

Complemented Cells.

WT L22

M L22

N281 {pLF 1.0) (E)

37.7

62.3

N281 (pLF 1.0) (E)

36.1

N281 (pLF 1.0) (NE)

100

63.9
*

N281 (pLF 1.0) (NE)

100

*

Average (E)

36.9 ± x.13 63.1± 1.13

Average (NE)

100 ± o.oo *

Strain + Plasmid

WT L4

M L4

N282 (pLF 4.6) (E)

12.7

87.3

N282 (pLF 4.6) (E)

19.6

80.4

N282 (pLF 4.6) (NE)

73.3

26.7

N282 (pLF 4.6} (NE)

73.0

27.0

N282 (pl«F 4.6) (NE)

69.0

31.0

Average (E)

16.2 ± 4.B8 83.8 i 4.8B

Average (NE)

71.8 1 2.40 28.2 1 2.40

(E) 300 ug/ml Erythromycin; (NE) No Erythromycin; * = Not
Detected; Data for each complementented mutant is summarized
from each section of the table aB an average value i one
standard deviation.

Figure 12.

PLASMID ISOLATION FROM COMPLEMENTED CELLS.

All

plasmidB used for quantification were digested with EcoRl.
Lanes 1*2:

Plasmids pLF 1.0 (lane 1) and 4.6 (lane 2)

isolated from strain SK901.

Lanes 3-4:

Plasmid pLF 1.0

isolated from strain N281 grown in the absence (lane 3) and
presence (lane 4) of erythromycin. Lanes 5-6:

Isolation of

plasmid pLF 4.6 from strain N282 grown in the absence (lane
5) and presence (lane 6) of erythromycin.

The positions of

the vector and insert bands are indicated.

1 2

3 4 5 6

-^Vector

4.6

-*

1.0
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Table 4.

Quantitation of Plasmid DNA from Complemented

Cells.

integrated Intensity
Strain + Plasmid

V/i ratio
pBR325

Insert

SK901 (pLP 1.0) (NE)

0.257

0.092

2.793

SK901 (pLF 4.6) (NE)

0.277

0.119

2.328

N281 (pLF 1.0) (NE)

0.391

0.113

3.460

N281 (pLF 1.0) (E)

0.415

0.140

2.964

N282 (pLF 4.6) (NE)

0.317

0.138

2.297

N282 (pLF 4.6) (E)

0.358

0.186

1.925

NE = No Erythromycin,* E - 300 ug/ml Erythromycin; V/I Ratio ■
pBR325 intensity/insert intensity
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wild type versus mutant protein in the ribosomes from strain
N282 (pLF 4 .6 ) assembled under each condition.

This was

possible since N282 ribosomes have been reported to have no
binding of the drug, while wild type and N281 ribosomes have
stoichiometric binding of erythromycin {Wittmann et al.,
1973).

As Table 5 demonstrates ribosomes from strain N282

(pLF 4.6) grown under each condition bound the expected
amounts of radiolabeled drug.

This prediction was based on

two-dimensional electrophoresis results obtained for the Bame
ribosomes and binding data collected for ribosomes from
strains SK901 and N282 alone.

Since ribosomes from strain

N282 showed no binding of the drug, the percentage of
wildtype protein from cells grown under each condition
(obtained from the electrophoresis results) was multiplied by
the percentage of erythromycin binding for wildtype
ribosomes.

This allowed a drug binding prediction to be made

for ribosomes isolated from complemented cells grown under
both conditions.
Ribosomal Degradation Analysis

Virtually all of the extensive work on erythromycin has
centered on its mechanism of translational inhibition.

The

observation that the molar concentration of erythromycin
required to affect translation in vitro is significantly
greater than that in vivo (Corcoran, 1984) adds support to
the concept of a second inhibitory mechanism.

The

complementation work done in this project supports such a
hypothesis as well.

Recently, Vester and Garrett (1987) have
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Table 5.

t14C]-Erythromycin Binding to 70S Ribosomes.

% Erythromycin
Bound

Predicted
Binding

100 / 0.0

77.0 + 1.08

NA

N281

0.0 / 100

64.5 ± 3.22

1NA

N282

0.0 / 100

0.0 ± 0.00

NA

N282 (4.6) (NE)

71.8/28.2

49.7 ± 2.33

55.3

N282 (4.6) (E)

16.2/83.8

0.0 + 0.00

12.5

Strain

2D Gels
WT / M

SK901

WT = percent wild type protein; M *= percent mutant protein;
NA - not applicable; % Erythromycin Bound = pmol [14C] erythromycin bound/ pmol 70S ribosome x 100; A prediction of
the binding percentage for complemented strains was
calculated by multipling the percent wildtype L4 found in 2D
gels by the percent erythromycin binding for SK901 ribosomes.
All binding percentages represent an average of three points t
one standard deviation.

57
proposed that erythromycin may stimulate 50S subunit
degradation.

If true, this would represent a secondary

mechanism capable of explaining these observations.
In order to examine this possibility, ribosomes in wild
type cells were prelabeled with [3H] uridine and then exposed
to an inhibitory concentration of erythromycin.

To assure

adequate incorporation of label, the cells were grown in
tryptone broth, which is a poorer medium than L broth but
advantageously contains no uridine.

As a result, the cells

grow more slowly and a lower concentration of the drug is
required for inhibition.

Under these conditions 75 ug/ml of

erythromycin was sufficient to limit cell growth by about
80%.

After cells reached their final densities they were

collected and lysed.

Ribosomal subunits were then separated

on sucrose gradients and sedimentation profiles were
constructed using the counts per minute of pH]-uridine and
the absorbance at 260 nm per fraction (Figures 13A and B).
If degradation of ribosomes occured in the presence of the
drug, the 50S subunit radioactivity peak would be expected to
disappear or at least decline significantly.
did not occur.

However, this

As Figure 13B shows, ribosomes prelabeled

with pH]-uridine in the absence of the antibiotic were fairly
stable during growth in the presence of the drug, showing a
subunit radioactivity ratio reasonably close to that normally
ejected (Table 6).

However, the effect of erythromycin on

assembly can be seen in the reduced amount of 50S subunits,
reflected in the altered A^,, ratio of the subunits.

This
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Figure 13.

RIBOSOMAL SUBUNIT DEGRADATION ANALYSIS.

Ribosomal subunits fran strain SK901 were prelabeled by
growth in I3H]-uridine.

After dilution and uridine addition,

the cells were grown in the presence or absence of
erythromycin {75ug/ml).
20% sucrose gradients.

Subunits were then separated on 5The A260 (□) and cpm (•) profiles for

subunits formed in the absence (A) and presence (B) of
erythromycin were plotted.

2500
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Table 6.

Characteristics of Ribosomal Subunits from Cells

Labeled in the Absence of Erythromycin.

Sanqple

5OS cum
30S cpm

SOS A2£0
3OS Aaso

50S
cpm/Aaeo

3OS
cpm/Aaso

S.A.
Ratio

SK901 (NE)

1.70

1.78

4,451

4,683

0.95

SK901 (E)

1.45

1.15

5,630

4,468

1.26

cpm/Aaeo = specific activity (S.A.); NE - no erythromycin; E =
75 ug/ml erythrooiycin; S,A Ratio = SOS S.A./30S S.A.; All
controls were repeatable within one standard deviation.
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result indicates that the antibiotic has a specific effect on
the biosynthesis (and not the degradation) of the large
ribosomal subunit in £. coli cells.
Ribosomal Assembly Analysis

This work was initiated to examine the hypothesis that
macrolides might affect the formation of ribosomes in
addition to their well established effects on translation.
Ribosomal subunit assembly was monitored using a method
previously described to study the assembly of ribosomes in
several temperature-sensitive protein synthesis mutants
(Champney, 1979).
The analysis was begun by labeling cells with [3HJ uridine for several generations in the presence or absence of
erythromycin (75 ug/ml). The radiolabeled subunits were
separated from cell lysates by sucrose gradient
centrifugation.

Figure 14A shows a control gradient of

ribosomal subunits from cells grown without erythromycin.

As

expected, a constant specific activity (cpm/A3G0) was found
for each subunit and the 50S/30S specific activity ratio was
1.0 (Table 7).

in contrast, ribosomes formed during growth

in the presence of erythromycin revealed a 50S subunit
deficit (Figure 14B). The 50S/30S specific activity ratio
for those ribosomes fell to 0.73.

The fact that the specific

activity ratio was less than 1 indicates that the effect was
specific to the large subunit.

Prolonged growth in the

presence of erythromycin prior to labeling made this point
even clearer.

Gradients from cells labeled in this fashion
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Figure 14.

RIBOSOMAL SUBUNIT ASSEMBLY ANALYSIS.

Ribosomal

subunits from strain SK901 were labeled with [3H] -uridine in
the absence (A) or presence of erythromycin (75 ug/ml)
beginning one (B) or five hours (C) after the addition of
The A^q (P) and cpm (•) of each fraction was then

drug.

plotted.
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Table 7.

Characteristics of Riboscmal Subunit Assembly in

the Presence of Erythromycin.

Sample

SOS cum
3OS cpm

50S A26D
30S Aaeo

50S
cpm/AsGo

30S
Cpm/Aaeo

S.A.
Ratio

SK901 (NE)

1.84

1.81

43,362

42,706

1.02

SK901 (El)

0.98

1.35

27,307

37,475

0.73

SK901 (E2)

0.68

1.31

20,291

39,099

0.52

15201 (NE)

1.58

1.B2

452,759

523,126

0.87

N281 (75)

1.39

1.61

496,768

576,509

0.86

N281 (300)

0.79

1.13

199,377

284,505

0.70

N281 (450)

0.81

1.25

134,372

207,572

0.65

N282 (NE)

1.74

1.84

426,771

450,182

0.95

N282 (75)

1.86

1.94

486,404

508,504

0.96

N282 (300)

1.72

1.88

242,074

264,341

0.92

N282 (450)

1.29

1.47

205,022

233,468

0.88

cpm/Aaeo - specific activity (S.A.); NE = no erythromycin; El
= 75 ug/ml erythromycin, 10 hr. label; E2 = 75 ug/ml
erythronycin, 6 hr. label; (Number) = ug/ml erythromycin; All
controls were repeatable within one standard deviation.
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showed that 50S biosynthesis was depressed even further over
time (Figure 14C), showing a specific activity ratio of 0.52
(Table 7).

Assembly Analysis of Mutant Ribosomes

Having established that erythromycin specifically
inhibits 50S subunit assembly, ribosomes from the
erythromycin resistant mutants N281 and N282 were examined
for assembly defects in the same manner as those from the
wild type strain SK901.

Several different concentrations of

erythromycin were used as it was expected that a higher
concentration of erythromycin would be required to see an
assembly effect, if one occurred.
Unlike wild type cells, neither mutant showed an
assembly defect at a concentration of 75 ug/ml erythromycin
(Figures 15B and 16B}. At a concentration of 300 ug/ml, a
limited effect on assembly was observed in strain N281
(Figure 15C), and at 450 ug/ml a reduction in 50S assembly
was found similar to that observed in wild type cells at 75
ug/ml (Figure 15D and Table 7).

In contrast, no assembly

defect was observed in strain N282 at 300 ug/ml erythromycin
(Figure 16C). At the highest erythromycin concentration
tested (450 ug/ml), only a limited effect on assembly was
observed (Figure 16D and Table 7).
Assembly Effects of Related Drugs

It is well known that certain alterations in the central
loop of domain V of the 23S rRNA secondary structure can

Figure 15.

SUCROSE GRADIENT ANALYSIS OF STRAIN N281

RIBOSOMES.

Ribosomal subunits from strain N281 were prepared

as before to examine assembly.

The subunits were labeled in

the absence (A) or presence of 75 (B); 300 (C); or 450 ug/ml
erythromycin (D). The A ^ (□) and cpm (•) of each fraction
was then plotted.
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SUCROSE GRADIENT ANALYSIS OF STRAIN N282

RIBOSOMES.

Ribosomal subunits from strain N282 were prepared

as before for assembly analysis.

The subunits were labeled

in the absence (A) or presence of 75 (B); 300 (C); or 450
ug/ml erythromycin (D). The A260 (□) and cpm (•) of each
fraction was then plotted.
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produce so called MLS antibiotic resistance.

To investigate

the generality of the assembly effect of erythromycin, two
other macrolides, a lincosamide, and a streptogramin were
examined for their abilities to inhibit 50S assembly.
Oleandomycin and spiramycin were chosen to represent the 14and 16-membered macrolides, while lincamycin and
virginianycin MA were selected to represent the remaining drug
groups.

Neither of the macrolides was found to effect 50S

subunit assembly when tested at concentrations which reduced
the rate of growth by 75% or more {Figures 17, 18 and Table
8),

Lincamycin (a lincosamide) appeared to have some effect

on assembly although it did not seem to be identical to that
of erythromycin (Figure 19A and Table 8).

Virginiamycin HL (a

streptogramin) on the other hand, did not have any noticeable
effect on assembly (Figure 19B). These results seemed to
indicate that erythromycin's effect on assembly was not
generally applicable to all members of the MLS resistance
group or, for that matter, to all macrolides (Table 8).
However, to test this idea further, two recently developed
derivatives of erythromycin A, azithromycin (9-deoxo-9amethyl-9a-aza-9a-homo-erythranycin A) and clarithromycin (6O-methylerythromycin) were examined as well.

These two drugs

have been modified to prevent the breakdown which occurs to
erythromycin at low pH.

Interestingly, azithromycin was

found to be as effective as erythrcnycin in inhibiting
assembly of the large subunit (Figure 20A). However,
clarithronycin did not inhibit assembly (Figure 20B and Table

Figure 17.

SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED

DURING GROWTH IN OLEANDOMYCIN.

RibOBOmal subunits from

strain SK901 were prepared as before for erythromycin
assembly experiments.

The subunits were labeled with [3HJ-

uridine in the presence of 80 (A) or 150 ug/ml (B)
oleandomycin.

The A260 {□} and cpm {•) of each fraction was

then plotted.
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Figure 18.

SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED

DURING GROWTH IN SPIRAMYCIN.

Ribosomal subunits from strain

SK901 were prepared as before for erythromycin assembly
experiments.

The subunits were labeled with [3H]-uridine in

the presence of 80 (A) or 150 ug/ml (B) spiramycin.
(□} and cpm (•) of each fraction was then plotted.
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Figure 19.

SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED

DURING GROWTH IN LINCOMYCIN AND VIRGINIAMYCIN M^

Ribosomal

subunits from strain SK901 were prepared as before for
erythromycin assembly experiments.

The subunits were labeled

with pH] -uridine in the presence of 75 ug/ml lincamycin (A)
or 20 ug/ml Virginiamycin Mi {B). The A260 (0)
each fraction was then plotted.
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Table 8. Characteristics of Ribosomal Subunit Assembly in
the Presence of Other Drugs.

5JQS_CBH
3os cpm

50S Aaco
30S Aaeo

50S
cpm/Aaco

3OS
cpm/Aaeo

S.A.
Ratio

SK901(080)

1.86

1.91

318,603

327,467

0.97

SK901(0150)

1.78

1.84

328,811

340,717

0.97

SK901(S80)

1.74

1.85

274,197

291,035

0.94

SK901 (S150)

1.89

1.74

295,503

272,382

1.08

SK901(L75)

1.30

1.30

205,353

205,111

1.00

SK90KV20)

1.77

1.89

82,435

88,433

0.93

SK901(A2.5)

0.94

1.36

113,796

163,734

0.70

SK901(C20)

1.68

1.70

103,389

103,906

1.00

Sample

cpm/Aaco « specific activity; (Letter Number) *= Drug, pg/ml
Drug; o = oleandomycin; S = spiramycin; V = virginiamycin MlfL » lincamycin; A = azithromycin; C = clarithromycin; All
controls were repeatable within one standard deviation.

Figure 20.

SUCROSE GRADIENT ANALYSIS OF RIBOSOMES FORMED

DURING GROWTH IN AZITHROMYCIN AND CLARITHROMYCIN.

Ribosomal

subunits from strain SK901 were prepared as before for
assembly experiments. The subunits were labeled with [3H] uridine in the presence of 2.5 ug/ml azithromycin (A) or 20
ug/ml clarithromycin (B). The A2S0 {□} and cprn (•} of each
fraction was then plotted.
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Chapter 4
Discussion

This work began as an attempt to better define the
interaction(s) between erythromycin and the £. coll ribosome
by identifying ribosomal protein sequences important for
resistance.

As is often the case in studies of this nature,

mutants exhibiting an altered phenotype for the
i

characteristic under examination can frequently be useful in
probing any interactions which may exist.

The strains (N281

and N2B2) used in these experiments were originally isolated
as spontaneous mutants resistant to high concentrations of
erythromycin (Apirion, 1967) and, therefore provided a useful
tool for the examination of this ribosome-drug interaction.
Previous analysis of ribosomal proteins from mutant N281
revealed that protein L22 possessed an altered
electrophoretic mobility at pH 8.6 (Wittmann et al., 1973).
However, the protein responsible for resistance in mutant
N282 could not be detected using this method.

Analysis of

the L4 protein from this mutant on a carboxymethyl cellulose
column indicated that the protein had an altered elution
profile at pH 5.6.

Based on the Buccess of this low pH

separation, an alternate two-dimensional electrophoresis
technique (at similar pH) was employed in this work.

As

expected, both mutant proteins showed an altered firstdimension mobility in the second gel system.
In order to more precisely define the nature of the
alterations in these mutants, the appropriate ribosomal
76

protein genes were sequenced from each resistant mutant.

The

wild type sequences found for the rplV and rplD genes agreed
exactly with those reported by ZurawBki and Zurawski (1985)
with one exception.

The rplD sequence contained a CAG codon

for Gin at position 30 in place of the reported CAA codon
which also codes for that amino acid (Zurawski and Zurawski
1965).

unlike the the point mutation found in the rplD gene

of the L4 mutant, the deletion of nine nucleotides from the
rplV gene of the L22 mutant was somewhat unexpected.

Close

examinination of the deleted region for possible secondary
structures using the DMA analysis program *DNASISW revealed
that a reasonably stable stem-loop structure (-1.2 kcal/mole)
was possible (Figure 21).

significantly, the deleted region

of the rplV gene was entirely contained in the loop.

It

seems likely that this area might be susceptible to
deoxyribonuclease activity and therefore to deletion.
The altered electrophoretic mobilities detected for
these proteins would predict a more negative form of each
protein.

Both the lysine to glutamate alteration in 1A

(N282) and the Met-Lys-Arg deletion found in L22 (N281) are
entirely consistent with this prediction.

One apparent

inconsistency is the fact that wittmann et al. (1973) were
unable to detect an elctrophoretic mobility change for the L4
protein of mutant N282 at pH 8.6.

This is most likely

explained by the lack of reference points near that protein
in the pH 6.6 electrophoretic system.

A small change such as

the one likely to occur would be difficult to detect.
identification of these sequence alterations is quite

The

Figure 21.

PROPOSED SECONDARY STRUCTURE FOR THE

DELETION REGION.

r p lV

GENE

Possible stem-loop structure for the

deleted region of the L22 gene.
boundaries of the deletion.

Arrows indicate the

The four base repeats flanking

the deletion are enclosed in boxes.

A=T
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significant.

Their identification represents the first

sequence changes to he reported for ribosomal proteins from
an erythromycin-resistant mutant.

These studies also

identify critical components of the sequences of two
different ribosomal proteins necessary for the interaction of
erythromycin with the bacterial ribosome.

These observations

should help in identifying the important amino acid and
nucleotide residues involved in the binding and inhibitory
effects of the compound.
A comparison of the altered protein sequences from the
mutants used in these experiments with the homologous
ribosomal proteins of several other organisms revealed that
both regions are highly conserved (Tables 9 and 10).

The

sequence surrounding the L4 mutation site shows canplete
identity in 2£. nseudotuberculosis and strong homology with
the Mycoplasma homolog (Table 9).

The altered region of

protein h22 also demonstrated strong homology with sequences
from two other prokaryotic L22 hamologs (Bacillus and
Mycoplasmal (Table 10).

In the four chloroplast genes

examined additional significant homology was observed with
the region surrounding the L22 deletion site.

The fact that

ribosomes from these cells and plastids are sensitive to
erythromycin (Mets and Bogorad, 1971; Qcmira, 1984) is
compelling evidence for the importance of these regions in
the erythromycin-ribosome interaction.

This point is

strengthened by the fact that L22-like sequences from
archaebacteria and rat (Arndt et al., 1990; Laine et al.,
1991) which show little sensitivity to these drugs (Amils et
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Table 9. Ribosomal Protein L4 Homologies

Organism

Sequence

ft Homology

Reference

Escherichia

PWRQgGTGR

100

(Zurawski and
Zurawski 1985)

Yersinia

FWRQXGTGR

94.5 (210)

(Gross et al., 1989)

Mycoplasma

PWKQKGTGL

35.8 (193)

(Ohkubo et al, 1987}

(201)

coll
psuedotuber.
capricolum

Residues altered in erythromycin-resistant ribosomal proteins
are double underlined.

Identical amino acids from L4

homologs in other organisms are in bold.

The percent of

overall sequence homology is given along with the total
number of amino acids in each homolog which is indicated in
parentheses.
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Table 10.

Ribosomal Protein L22 Homologies.

Organism

Sequence

ft.-HOmology

Escherichia

QPSMKRIMP

100

GPTLKRFRP

54.1 (109)

(Ohkubo et al., 1987)

GPTLKRFRP

52.8 (108)

(Kroner et al., 1990)

Liverwort
(chloroplast)

gtffkrfqp

41.6 (101)

(Fukuzawa et al.,
1988)

Red algae
(chloroplast)

GPKLKRFQP

40.6 (101)

(Kao and Hu, 1990)

Spinach
(chloroplast)

OITLKKVKP

38.1 (97)

(Zhou et al., 1989)

Tobacco
(chloroplast)

GTTVKKLKP

37.6 (101) (Tanaka et al., 1986)

Rat liver

APKMRRRSG

32

Halobacteriuro

VGESQGRKP

17.8 (90)

(110)

£Qli
Mycoplasma

Reference

(Zurawski and
Zurawski, 1985)

caprlcolum
Bacillus

stearotherm.

(109) (Laine et al., 1991)
(Arndt et al., 1990)

marismortui

Residues altered in erythromycin-resistant ribosomal proteins
are double underlined.

Identical amino acids from L22

homologs in other organisms are in bold.

The percent of

overall sequence homology is given along with the total
number of amino acids in each homolog which is indicated in
parentheses.
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al., 1990) also have poor homology.

These results suggest

that ribosomes from other prokaryotes, or from mitochondria
that have significant sequence homology to £. coli ribosomal
proteins L4 and L22 should be sensitive to inhibition by
erythromycin, as was demonstrated previously (Lamb et al.,
1968).
A number of recent studies have identified several 23S
ribosomal RNA mutations in £. cflli (Douthwaite, 1992;
Ettayebi et al., 1985; Sigmund and Morgan, 1982) and other
organisms { Vester and Garrett, 1987 and references therein)
which also lead to the erythromycin resistance phenotype.
These sequence changes are almost exclusively located in
domain V of the RNA secondary structure with the exception of
one deletion affecting domain II described b y Douthwaite et
al. (1985).

This is a significant finding when one considers

that proteins 14 and L22 interact with each other in binding
to 23S rRNA at sequences associated with domain II (Herold
and Nierhaus, 1987).
These experiments have also provided evidence that
erythromycin has a second mechanism of action.

Perhaps the

first clue to this was the observation that the expression of
wild type and mutant alleles in merodiploid cells was
different in the presence and absence of the drug.

Two-

dimensional electrophoresis of ribosomal proteinB from
particles formed under each condition demonstrated this
clearly.

Those experiments showed that a considerable excesB

of wild type protein was present in ribosomal particles from
cells grown under permissive conditions (no erythromycin
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present) while mutant protein predominated in the presence of
the drug.

This difference in protein content waB alBO

reflected in the relative sensitivity of the two complemented
mutants to increasing concentrations of erythromycin. The
L22 diploid was far more sensitive to higher concentrations
of the macrolide than it's L4 counterpart was under the same
conditions.

A quantitative comparison of the relative

expression of these genes revealed that plasmid copy number
differences were not a factor in the distribution of protein
forms.
However, it is conceivable that transcription might be
effected in the presence of the L4 plasmid (pLF 4.6) since
expression of the S10 operon is under autogenous control of
protein L4.

Termination of trancription for the operon is

specically elevated with increasing concentrations of free L4
(Zengel and Lindahl, 1990).

under those conditions one would

expect to see a decrease in the ratio of mutant versus wild
type protein conpared to that of the L22 proteins, since pLF
4.6 transcription would be independent of that regulation.
However, this was not the case, possibly this is due to the
alteration present in the mutant form of L4.

It is possible

that the mutant protein is not capable of the same regulatory
function or at least is not as efficient.

Such questions can

only be answered by quantifing mRNA levels from both the
plasmid and the chromosomal genes, since the two are under
the control of different promoters.
Further evidence for a second mechanism was provided by
the fact that differences in binding affinities for the drug

have been observed for each of these mutants.

Previous

examination of ribosomes from the 1A mutant showed that they
bound erythromycin poorly and had a reduced
peptidyltransferase activity.

Curiously, neither of these

features were found for ribosomes isolated from the L22
mutant {wittmann et al., 1973).

These results agree with the

binding data reported here, although somewhat less binding
was found in these experiments compared with that reported by
Wittmann et al. (1973).

This is most likely a result of the

inactivation of a greater percentage of ribosomes during the
purification process.

Given these results, the basis for

resistance in the L22 strain seemed less clear.

However, the

possibility of a second mode of action for the drug seemed
more likely.
The assembly experiments presented here provide strong
evidence that erythromycin has two independent but related
effects on protein biosynthesis in Escherichia coli cells.
The functional effect of this antibiotic is to prevent the
elongation of short polypeptide chains during translation,
interfering with a step after initiation (Andersson and
Kurland, 1987; Vester and Garrett, 1987).

This work also

shows that an additional structural effect of the compound is
to block ribosomal subunit formation, probably early in the
assembly process.

SOS subunit formation is specifically

affected, since breakdown is not stimulated and the 30S
subunit is unaffected.

These results differ from the

conclusion of Vester and Garrett (1987) that erythromycin
apparently stimulated the degradation of 5OS subunits in a
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merodiploid strain containing 23S rRNA alleles for
sensitivity and resistance to erythromycin.

However,

differences in strains and experimental conditions makes a
direct comparison with these results difficult.

It is

important to note the the efficacy of erythromycin and
azithromycin in vivo is much greater than that of
oleandomycin, clarithromycin or spiramycin, consistent with
the two site effect of the former compounds (Nakayama, 1984;
Whitman and Tunkel, 1992) .
Although the MLS resistance drug group does not appear
to effect assembly as a whole, it is still not clear from
this work whether other members of this drug group might have
an effect,

it is clear however, that the macrolide effect on

assembly is restricted to erythromycin and azithromycin among
the antibiotics examined here.

A number of studies have

indicated that erythronycin interacts with both sequences in
the 23S ribosomal RNA and with ribosomal proteins L4 and L22
(Arevalo et al., 1988; Coopeman et al., 1990; Douthwaite et
al., 1985; Ettayebi et al., 1985; Moazed and Noller, 1987;
Sigmund and Morgan, 1982; Teraoka and Nierhaus, 1978).

Since

the assembly defect is significantly reduced in resistant
mutantB with an altered L22 or L4 protein, it seems clear
that these proteins are part of the binding site for the drug
on the 50S subunit.
These results suggest a model for the effect of
erythronycin on assenibly, based on two facts.

A comparison

of the structures of erythromycin and azithrontycin (which
prevent assembly) and of oleandomycin and clarithromycin

(which do not), reveals that the former compounds contain a
pair of cis hydroxyl groups at positions 6 and 12 of the
macrolactone ring (Figure 22).

Oleandomycin lacks both of

these hydroxyl groups and clarithromycin is a 6-0methylerythranycin (Nakagawa and Ontura, 1984; Whitman and
Tunkel, 1992).

This inplies that the 6-OH group is important

in promoting the assembly deficiency.

In addition, the

mutational change in protein L4 conferring assembly
resistance involves the loss of a baBic amino acid residue.
I propose that erythromycin (and azithromycin) interferes
with the binding of L4 to 23S rRNA early in the assembly
process and that an electrostatic interaction between the 6OH group of the drug and Lys 63 of L4 is critical for this
effect.

Loss of the positive charge (as in the mutant

strain) or the absence of the 6-hydroxyl group (as in
oleandonycin and clarithromycin) would allow assembly to
proceed.

Protein L4 is a strong 23S rRNA binding protein

associating with the 5f end of the RNA (Nierhaus, 1982).

It

is also noteworthy that the erythronycin-resistant mutant
N282 is cold-sensitive for growth at 20°C, and is 50S subunit
assenbly defective under those conditions (Champney,
unpublished observations). This subunit assembly defect has
been observed for several other cold-sensitive mutants
(Bryant and Sypherd, 1974; Guthrie et al., 1969) including a
strain with an L22 protein mutation (Pardo et al.r 1979).
Apparently the price for resistance to erythronycin in the L4
mutant is ribosomal instability at low tenperature.
These findings suggest two important directions to be
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Figure 22. MACROLIDE drug structures . Molecular structures
of erythromycin a , oleandomycin, azithromycin, and
clarithromycin.

Hydroxyl groups at positions 6 and 12 (as

they relate to erythromycin A's structure) are indicated in
bold.

HO -------

ERYTHROMYCIN A

OLEANDOMYCIN

AZITHROMYCIN

CLARITHROMYCIN

pursued.

The in vitro reconstitution of the large subunit

should be performed in the presence of erythromycin to help
define the site and stage in assetribly at which the inhibition
occurs.

It will also be important to test other

microorganisms (especially Gram positive cells) to explore
the generality of this novel effect of the macrolide
antibiotic drug group on ribosome formation.
Finally, these results indicate a second parameter to be
evaluated when new macrolide antibiotics are under review for
effectiveness.

This pronounced effect on riboscmal assembly

indicates that this may be an equally important target for
drug activity as is an inhibition of translation.

It is also

important to be reminded that the idea of "one drug one
action" is not necessarily true.
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